Open Access Activated Leukocyte Cell Adhesion Molecule in Breast Cancer: Prognostic Indicator

IntroductionActivated leukocyte cell adhesion molecule (ALCAM) (CD166) is an immunoglobulin molecule that has been implicated in cell migration. The present study examined the expression of ALCAM in human breast cancer and assessed its prognostic value.MethodsThe immunohistochemical distribution and location of ALCAM was assessed in normal breast tissue and carcinoma. The levels of ALCAM transcripts in frozen tissue (normal breast, n = 32; breast cancer, n = 120) were determined using real-time quantitative PCR. The results were then analyzed in relation to clinical data including the tumor type, the grade, the nodal involvement, distant metastases, the tumor, node, metastasis (TNM) stage, the Nottingham Prognostic Index (NPI), and survival over a 6-year follow-up period.ResultsImmunohistochemical staining on tissue sections in ducts/acini in normal breast and in breast carcinoma was ALCAM-positive. Differences in the number of ALCAM transcripts were found in different types of breast cancer. The level of ALCAM transcripts was lower (P = 0.05) in tumors from patients who had metastases to regional lymph nodes compared with those patients without, in higher grade tumors compared with Grade 1 tumors (P < 0.01), and in TNM Stage 3 tumors compared with TNM Stage 1 tumors (P < 0.01). Tumors from patients with poor prognosis (with NPI > 5.4) had significantly lower levels (P = 0.014) of ALCAM transcripts compared with patients with good prognosis (with NPI < 3.4), and tumors from patients with local recurrence had significantly lower levels than those patients without local recurrence or metastases (P = 0.04). Notably, tumors from patients who died of breast cancer had significantly lower levels of ALCAM transcripts (P = 0.0041) than those with primary tumors but no metastatic disease or local recurrence. Patients with low levels of ALCAM transcripts had significantly (P = 0.009) more incidents (metastasis, recurrence, death) compared with patients with primary breast tumors with high levels of ALCAM transcripts.ConclusionsIn the present panel of breast cancer specimens, decreased levels of ALCAM correlated with the nodal involvement, the grade, the TNM stage, the NPI, and the clinical outcome (local recurrence and death). The data suggest that decreased ALCAM expression is of clinical significance in breast cancer, and that reduced expression indicates a more aggressive phenotype and poor prognosis.

[1]  O. Pourquié,et al.  BEN/SC1/DM-GRASP, a homophilic adhesion molecule, is required for in vitro myeloid colony formation by avian hemopoietic progenitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Mansel,et al.  Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer , 2004, Clinical & Experimental Metastasis.

[3]  J. Hornaday,et al.  Cancer Facts & Figures 2004 , 2004 .

[4]  G. Watkins,et al.  Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[6]  W. Birchmeier,et al.  Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. , 1993, The American journal of pathology.

[7]  H. Phillips,et al.  Molecular cloning and expression of a novel adhesion molecule, SC1 , 1991, Neuron.

[8]  R. Mansel,et al.  Expression of peroxisome‐proliferator activated receptor‐gamma (PPARγ) and the PPARγ co‐activator, PGC‐1, in human breast cancer correlates with clinical outcomes , 2003 .

[9]  L. Ellis,et al.  Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Y. van Kooyk,et al.  MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). , 1998, The American journal of pathology.

[11]  F. Tarentini Trojani.  [Tumors of the breast]. , 1987, La Clinica terapeutica.

[12]  B. Haynes,et al.  Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand , 1995, The Journal of experimental medicine.

[13]  R. Mansel,et al.  Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. , 2003, International journal of cancer.

[14]  W. Jiang,et al.  E‐cadherin and its associated protein catenins, cancer invasion and metastasis , 1996, The British journal of surgery.

[15]  G. Watkins,et al.  Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. , 2004, European journal of cancer.

[16]  J. Bajorath,et al.  Characterization of mouse ALCAM (CD166): the CD6‐binding domain is conserved in different homologs and mediates cross‐species binding , 1997, European journal of immunology.

[17]  F. Lottspeich,et al.  Neurolin, a cell surface glycoprotein on growing retinal axons in the goldfish visual system, is reexpressed during retinal axonal regeneration , 1992, The Journal of cell biology.

[18]  T. Suda,et al.  ALCAM (CD166): its role in hematopoietic and endothelial development. , 2001, Blood.

[19]  G. Swart.  Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. , 2002, European journal of cell biology.

[20]  J. Stephan,et al.  Distribution and function of the adhesion molecule BEN during rat development. , 1999, Developmental biology.

[21]  J. Sainsbury,et al.  ABC of breast diseases , 2000 .

[22]  I. Ellis,et al.  ABC of Breast Diseases: Prognostic Factors , 1994, BMJ.

[23]  I. Nazarenko,et al.  A closed tube format for amplification and detection of DNA based on energy transfer. , 1997, Nucleic acids research.

[24]  J. Rossier,et al.  BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Rebbeck,et al.  Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. , 2001, American journal of clinical pathology.

[26]  T. Suda,et al.  Mesenchymal Stem Cells in Perichondrium Express Activated Leukocyte Cell Adhesion Molecule and Participate in Bone Marrow Formation , 2002, The Journal of experimental medicine.

[27]  W. Jiang,et al.  Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model. , 2001, Biochemical and biophysical research communications.

[28]  J. Berg,et al.  TUMORS of the breast. I. , 1954, Medical times.

[29]  O. Pourquié,et al.  An antigen expressed by avian neuronal cells is also expressed by activated T lymphocytes. , 1992, Cellular immunology.

[30]  H. Bush,et al.  Breast Cancer Research , 1978, British Journal of Cancer.

[31]  J. J. van den Oord,et al.  Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. , 2000, The American journal of pathology.

[32]  W. Jiang,et al.  Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells. , 2000, The Journal of urology.

[33]  K. Kondo,et al.  A candidate high density lipoprotein (HDL) receptor, HB2, with possible multiple functions shows sequence homology with adhesion molecules. , 1998, Journal of atherosclerosis and thrombosis.

[34]  E. Geisert,et al.  Distribution and characteristics of a 90 kDa protein, KG-CAM, in the rat CNS , 1994, Brain Research.

[35]  O. Pourquié,et al.  The characterization, molecular cloning, and expression of a novel hematopoietic cell antigen from CD34+ human bone marrow cells. , 1997, Blood.

[36]  S. Loening,et al.  ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions , 2003, The Prostate.

[37]  C. Myers,et al.  Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. , 2000, Biochemical and biophysical research communications.

[38]  A. Gown,et al.  E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. , 2001, American journal of clinical pathology.

[39]  C. Figdor,et al.  Molecular Basis for the Homophilic Activated Leukocyte Cell Adhesion Molecule (ALCAM)-ALCAM Interaction* , 2001, The Journal of Biological Chemistry.

[40]  R. Mansel,et al.  Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[41]  J. Kamholz,et al.  DM-GRASP, a novel immunoglobulin superfamily axonal surface protein that supports neurite extension , 1991, Neuron.

[42]  J. Schalken,et al.  Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. , 2000, Biochemical and biophysical research communications.

[43]  G. Watkins,et al.  The Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer , 2004, Clinical Cancer Research.